Our voices regarding treatment-related side effects have been heard!
Earlier this year, the Patient-Centered Dosing Initiative presented the results of an MBC Patient Survey about the prevalence and severity of treatment-related toxicities to the FDA.
The result of this and similar endeavors is that the FDA has now begun advocating for Phase 1 Clinical Trials to release at least 2 doses for subsequent study in subsequent randomized trials, instead of the Maximum Tolerated Dose.
Feel free to watch the 11/10/21 conference with the FDA, Pharma, Friends of Cancer Research, and myself: youtube.com/watch?v=tO_Ta9K...